Clinical Trials Logo

Acute Graft Versus Host Disease clinical trials

View clinical trials related to Acute Graft Versus Host Disease.

Filter by:

NCT ID: NCT01475162 Terminated - Clinical trials for Acute Graft Versus Host Disease

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Start date: August 8, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This trial designed to evaluate the toxicity and efficacy of tocilizumab in the treatment of steroid refractory acute graft versus host disease (GVHD).

NCT ID: NCT01220297 Terminated - Leukemia Clinical Trials

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Start date: August 2006
Phase: Phase 2
Study type: Interventional

A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)

NCT ID: NCT01140984 Terminated - Clinical trials for Acute Graft Versus Host Disease

Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)

Start date: September 2010
Phase: N/A
Study type: Interventional

Post allogeneic hematopoietic stem cell transplantation (HSCT) patients with steroid resistant acute GVHD localised to the liver will receive 24 hours continuous intra-arterial infusion of methylprednisolone.

NCT ID: NCT00282503 Terminated - Clinical trials for Acute Graft-versus-Host Disease

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days following an allo HPCT.

NCT ID: NCT00038792 Terminated - Clinical trials for Acute Graft Versus Host Disease

Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Start date: October 2000
Phase: Phase 1/Phase 2
Study type: Interventional

Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.

NCT ID: NCT00032773 Terminated - Clinical trials for Acute Graft Versus Host Disease

Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

Start date: January 30, 2002
Phase: Phase 1/Phase 2
Study type: Interventional

To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.